Mesothelin-targeted chimeric antigen receptors and methods of making them

Patent metadata

Field	Value
Publication number	US-10538588-B2
Application number	US-201815981142-A
Country	US
Kind code	B2
Filing date	May 16, 2018
Priority date	Jun 6, 2014
Publication date	Jan 21, 2020
Grant date	Jan 21, 2020

Abstract

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

First claim

What is claimed is:

1. A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular domain, wherein the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), wherein the scFv comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:11, (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:13, (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14, (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16.

2. The CAR of claim 1 , wherein the scFv is a human scFv.

3. The CAR of claim 1 , wherein the extracellular antigen-binding domain of the CAR recognizes human mesothelin with a mesothelin expression level of about 1,000 or more mesothelin binding sites/cell.

4. The CAR of claim 1 , wherein the scFv comprises (a) a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO:1.

5. The CAR of claim 1 , wherein the scFv comprises a light chain variable region comprising amino acids 1-107 of SEQ ID NO:5 or amino acids 1-107 of SEQ ID NO:3.

6. The CAR of claim 1 , wherein the scFv comprises:
(a) a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO:1; and a light chain variable region comprising amino acids 1-107 of SEQ ID NO:5; or
(b) a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO:1; and a light chain variable region comprising amino acids 1-107 of SEQ ID NO:3.

7. The CAR of claim 1 , wherein the extracellular antigen-binding domain specifically binds to human mesothelin with a binding affinity (K d ) of from about 1 nM to about 25 nM.

8. The CAR of claim 1 , wherein the scFv comprises a linker between a heavy chain variable region and a light chain variable region of the scFv.

9. The CAR of claim 1 , wherein the extracellular antigen-binding domain comprises a leader that is covalently joined to the N-terminus of the extracellular antigen-binding domain.

10. The CAR of claim 9 , wherein the leader comprises a CD8 polypeptide.

11. The CAR of claim 1 , wherein the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a CTLA-4 polypeptide, a PD-1 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, a BTLA polypeptide, or a combination thereof.

12. The CAR of claim 11 , wherein the transmembrane domain comprises a CD28 polypeptide.

13. The CAR of claim 1 , wherein the intracellular domain comprises a CD3ζ polypeptide.

14. The CAR of claim 1 , wherein the intracellular domain further comprises at least one co-stimulatory signaling region.

15. The CAR of claim 14 , wherein the at least one co-stimulatory signaling region comprises a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, or a combination thereof.

16. The CAR of claim 1 , wherein the transmembrane domain comprises a CD28 polypeptide and the intracellular domain comprises a CD3ζ polypeptide and a co-stimulatory signaling domain comprising a CD28 polypeptide.

17. The CAR of claim 1 , wherein the CAR is M28z.

18. The CAR of claim 17 , wherein the transmembrane domain of M28z comprises a CD28 polypeptide, and the intracellular domain of M28z comprises a CD3ζ polypeptide and a co-stimulatory signaling region comprising a CD28 polypeptide.

19. The CAR of claim 1 , wherein the CAR is recombinantly expressed or expressed from a vector.

20. The CAR of claim 19 , wherein the vector is a γ-retroviral rector.

21. An immunoresponsive cell comprising the CAR of claim 1 .

22. The immunoresponsive cell of claim 21 , wherein the immunoresponsive cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), a regulatory T cell, a human embryonic stem cell, and a pluripotent stem cell from which lymphoid cells may be differentiated.

23. The immunoresponsive cell of claim 21 , wherein the immunoresponsive cell is a T cell.

24. The immunoresponsive cell of claim 21 , wherein the immunoresponsive cell expresses from about 1 to about 4 vector copy numbers/cell of the CAR.

25. A nucleic acid encoding the CAR of claim 1 .

26. A vector comprising the nucleic acid of claim 25 .

27. A pharmaceutical composition comprising an effective amount of the immunoresponsive cell of claim 21 and a pharmaceutically acceptable excipient.

28. A kit for treating or preventing a neoplasm, a pathogen infection, an autoimmune disorder, an inflammatory disease, an allogeneic transplant, or graft rejection, comprising the immunoresponsive cell of claim 21 .

29. A method for producing an immunoresponsive cell that binds to human mesothelin, comprising introducing into the immunoresponsive cell a nucleic acid sequence that encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular domain, wherein the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), wherein the scFv comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:11, (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, (c) a heavy chain variable region CDR 3 comprising the amino acid sequence set forth in SEQ ID NO:13, (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14, (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16.

Assignees

• Memorial Sloan Kettering Cancer Center
• Us Health

Inventors

• Adusumilli Prasad S
• Sadelain Michel
• Dimitrov Dimiter S
• Feng Yang

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title